Although treatment of childhood acute myelogenous leukemia (AML) has substantially improved in the last 15 years, in nearly half of the patients disease recurs. The aim of this study was to establish the prognosis of relapsed childhood AML and to identify prognostic factors for achievement of second remission and survival. From February 1988 to July 1996, 134 children with first relapse of AML were reported to the study center of the AML-BFM group. 102 patients treated intensively to induce second remission were prospectively followed. With various regimens, complete remission was achieved in 52 of 102 patients (51%), 27 children were alive in median 2.5 years (range, 0.4-7 years) after relapse. Disease-free survival was observed in seven of 16 patients transplanted from a matched sibling donor, one of four after matched unrelated bone marrow transplantation, 10 of 22 after autologous transplantation and five of nine patients after chemotherapy alone (two patients were lost to follow-up). Time until relapse reflecting the duration of first remission is the only variable correlating CR and survival rates. Defining early relapse as less than 1.5 years from diagnosis to relapse resulted in a 5-year survival of 10%, s.e. 5% for early relapses and 40%, s.e. 10% for late relapses (P-logrank test, 0.0001). Duration of first remission is a strong predictor for achievement of second CR and survival. It should be considered in reporting results of experimental therapies.
Introduction
Prognosis of childhood acute myelogenous leukemia (AML) has significantly improved in the last 15 years 1,2 and longterm survival is reported for 40-50% of children. Only scant data are available on the general prognosis for children with relapsed AML. In adults with relapsed AML, prognosis is generally poor. 3 For pediatric patients, it is known that intensive second-line treatment induces remission in a proportion of patients and at least some of the children may have a chance of cure. 4, 5 In reports on experimental therapies evaluating drugs in phase II studies [6] [7] [8] patient numbers are usually small and long-term follow-up is rarely reported. Therefore no conclusions for the prognosis of children with relapsed AML can be drawn. In the German pediatric AML-BFM studies most of the patients with relapse were treated intensively to achieve second remission, despite the difficulties arising from the intensive pretreatment in front-line therapy. We could therefore analyze the efficacy of intensive treatment and probability of long-term survival in relapsed pediatric AML on the basis of 102 patients from two recent AML-BFM studies. We observed a probability of long-term survival of 21% and identified duration of first remission defined as time from first diagnosis until relapse as the only independent favorable prognos- tic factor resulting in a probability of 40% survival after 5 years for children with more than 1.5 years duration of first remission.
Patients and methods

Study design and data acquisition
More than 90% of children with AML in Germany are currently treated within the co-operative AML-BFM studies. All patients were followed prospectively in the interventional studies AML-BFM 87 and 93 (588 protocol patients with de novo AML from December 1987 to July 1996). Status of disease was monitored by regular recalls. In case of relapse, diagnostic procedures including central morphology were carried out. Further treatment was documented and response to therapy assessed in the reference laboratory by morphology. For patients entering the relapse studies AML-REZ 91 and 93, data on realization of treatment and toxicity were documented in detail. Follow-up data were updated on December 1996.
Study population
From February 1988 to July 1996, 134 children with first relapse of AML were reported to the study center of the AML-BFM group (121 protocol patients from studies AML BFM-87 and -93 plus 13 patients with other pretreatment). Of 28 patients treated palliatively (mainly early relapses, in median 0.8 years after diagnosis), 26 children died within 10 months (median 1.7 months) after diagnosis of relapse, one patient was lost to follow-up, another patient survived 2.5 years with an isolated cutaneous relapse.
Four children were directly transplanted in relapse, none survived. The remaining 102 patients were treated intensively to achieve second CR (Table 1) .
Median age at diagnosis of relapse was 8.1 years, ranging from 1-19 years. The distribution of FAB subtypes in relapse given in Table 2 shows a high percentage of M5 leukemias compared to the prevalence at first diagnosis (31% vs 22%) reflecting the unfavorable prognosis of the M5 subtype. Median time of first remission (time until relapse) was 1.1 years, ranging from 7 months to 15 years. As shown in Table 2 , most of the patients (63) relapsed early, about onethird (39) relapsed late after 18 months from initial diagnosis to relapse.
Treatment for relapse
Treatment in relapse study REZ-91 (15 patients) consisted of double induction of mitoxantrone (mitox), VP-16 (mitox 10 mg/m 2 /day, 30 min infusion day 1 and 2, VP-16 100 mg/m 2 /12 h, 120 min infusion for 5 days). In study REZ-93 (28 patients) mitox/VP-16 was followed by high-dose Ara-C/mitox (HAM: Ara-C 3 g/m 2 /12 h, 3 h infusion days 1-3 and mitox 10 mg/m 2 days 3 and 4, Figure 1 ). In both studies a subsequent 6-week consolidation and either allogeneic or autologous bone marrow transplantation (BMT) or maintenance therapy was carried out. Conditioning regimen for allogeneic BMT included busulfan/cyclophosphamide ± VP-16 or thio-
Figure 1
Treatment plan of study REZ-93 for relapsed AML. Ind I, induction I; BMA, bone marrow aspiration; CSF, cerebrospinal fluid.
tepa (and additional 12 Gy total body irradiation in eight patients); for autologous BMT busulfan/cyclophosphamide and in two patients busulfan + VP-16 50 mg/kg. In all other patients, therapies of similar intensity were applied to achieve a second remission. All patients were treated with at least one induction therapy including anthracyclines and high-dose Ara-C and a post-remission therapy with either several reinductions or a long consolidation followed by autologous or allogeneic bone marrow transplantation.
Statistical procedures Definitions:
Nonresponse was defined as persistence of more than 25% leukemic blasts in bone marrow. Partial response was defined as blast cell reduction Ͻ25% in the bone marrow or bone marrow aplasia without recovery of the peripheral neutrophil count Ͼ1500/l.
Survival was calculated from date of diagnosis to death of any cause or last follow-up. Kaplan-Meier's method 9 was used to estimate survival rates with comparisons based on the twosided log-rank test. The date of first remission was difficult to define, since treatment after induction was usually continued before standard remission criteria were fulfilled. Therefore duration of first remission was calculated from the time of initial diagnosis to diagnosis of relapse. For analysis of prognostic factors, a Classification and Regression Trees (CART) analysis 10, 11 was performed. All quantitative variables suspected to have an influence on survival where scanned for a cut-point which divided the 102 patients into groups with the highest possible risk ratio, given a minimum P value below 0.01 and a minimum group size of 20 patients.
For the graph in Figure 4 , the study population is partitioned into two groups according to time until relapse. Starting with 10 patients with short duration and 92 patients with longer duration until relapse, survival and CR rates are calculated for the group with longer remission. The calculation is repeated patient-wise and the result given as a graph. The remaining number of patients in the group is indicated in the Figure. We termed this calculation continuous partitioning; it demonstrates the influence of a quantitative variable on survival and CR rates.
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Results and discussion
Response to therapy and toxicity of treatment
We first analyzed response to therapy in the study population (Table 3) . A total of 52 (51%) of 102 patients achieved CR after one or two induction courses. Thirty-seven were nonresponders and 10 achieved partial remission. Overall, 27 of 102 patients (26%, including two patients lost to follow-up in CR) were alive in median 2.5 years (range 0.4-7 years) after relapse. Overall survival was 21%, s.e. 5% after 5 years ( Figure 2) .
Three (3%) of the patients died early during induction and are considered as treatment-related deaths. Long lasting marrow aplasia was the major cause of morbidity, resulting in severe infection (WHO grade 3 and 4) in 30% after first induction and 75% after second induction.
A CR rate of 50% was achieved in our study group compared to 35% recently reported by Steuber et al 12 and 73% reported by Wells et al 8 for a smaller group of pediatric patients. The estimated probability of 5-year survival in our group was 21% for all patients compared to 10-29% in adult patients. 13, 14 These favorable results are probably due to the application of other intensive induction regimen, eg with mitoxantrone, and VP-16 in escalated dose of 1000 mg/m 2 in patients who had received normal dose VP-16 and no mitox-
Figure 2
Probability of survival in 102 children treated for relapsed AML. -, All patients, n = 102, 75 events.
antrone in front-line therapy (AML-BFM 87). Furthermore in front-line therapy of the BFM studies, allogeneic BMT is only considered for high risk patients with an HLA-identical sibling donor, allowing for a more intensive treatment for relapse patients.
Efficacy of different induction and postremission therapy
The different induction regimen produced similar response and survival rates (Table 3) . Estimated probability of 5-year survival was 0.24, s.e. 13% in REZ-91, 0.28, s.e. 0.9% in REZ-93 and 0.20, s.e. 0.6% for other intensive regimen. Table 4 shows effects of different postremission therapies on survival. A total of 21 patients received an allogeneic transplant in second CR. None of the six patients transplanted after partial response survived. Seven of 16 patients transplanted from a matched sibling donor were still alive (follow-up in median 4.3, range 1.2-6.0 years), while only one of four survived (with a follow-up of 1 year) after matched unrelated BMT. Thus, BMT in proven second CR was mostly successful while BMT in partial remission was not.
Autologous transplantation resulted in an EFS of 45% (10/22 patients) after 5 years (follow-up, median 2.7, range 1.3-7.0 years) which is similar to allogeneic transplantation. This was due to a high transplant-related mortality in allogeneic BMT (22%) compared to autologous transplantation (9%), neutralizing the better antileukemic effect of allogeneic BMT. Similar data have been obtained in studies comparing autologous and allogeneic BMT in young adults with relapsed AML. 15 For autologous transplantation Vignetti et al 16 have recently reported a 41.5% EFS at 7 years in 48 children in second CR of AML.
In our study, five patients suffering mainly from late relapse (median 1.9 years) remained in CCR with chemotherapy alone (follow-up, median 1.4, range 0.4-5.1 years). In four of these five children, second remission meanwhile lasted longer than first remission. Thus, long-term survival could be achieved with chemotherapy alone in some patients.
Risk factors
The favorable overall results obtained in these patients allowed a statistical analysis for prognostic factors affecting CR rates and for the first time, long-term survival in children with relapsed AML. To identify prognostic factors for survival after relapse, we performed a multivariate analysis including the factors: leukocyte count; thrombocyte count initially and in relapse; hemoglobin; initial FAB subtype; FAB subtype at relapse; type of induction or postremission therapy; and time until relapse. The only independent variable affecting outcome was the time until relapse. The best predictive value was obtained taking a cutoff value at 1.5 years until relapse for the definition of early and late relapses. The discrimination results in a 5-year survival of 10%, s.e. 5% for early relapses and 40%, s.e. 10% for late relapses (P-logrank test 0.0001, Figure 3 ). Thus, time until relapse predicted long-term survival in a considerable proportion of pediatric patients whether treated with BMT or chemotherapy alone. Accordingly, Tomas et al 15 recently reported that duration of first remission predicted survival after second CR autologous and allogeneic BMT in young adults. Our findings allow a rational clinical decision on intensive relapse therapy in children, since time until relapse identifies patients with a 40% chance of 5-year survival after relapse.
Continuous increase of CR rates with duration of first remission
For adults with relapsed AML it has been reported 13, 17 that long duration of first remission is a prognostic factor for achievement of second CR. We therefore analyzed the prognostic value of time until relapse for the achievement of second CR. The graph in Figure 4 is obtained by continuous partitioning according to time until relapse and following calculation of CR rates (see Patients and methods section). In the total number of 102 patients the CR rate was 50%, and increases to 68% in those 56 patients relapsing after more than 1 year. A similar correlation was found for survival and
Figure 3
Probability of survival in early relapses vs late relapses.
J, Time from diagnosis until relapse Ͻ1.5 years, n = 63, 55 events. ۙ, Time from diagnosis until relapse Ͼ1.5 years, n = 39, 20 events.
Figure 4
Probability of achievement of second complete remission with increasing duration of first remission. The study population is partitioned into two groups according to time until relapse. Starting with 10 patients with short time and 92 patients with longer time until relapse, CR rates are calculated for the group with longer remission. The calculation is repeated patient-wise (continuous partitioning) and the result given as a graph. The remaining number of patients in the group is indicated. time until relapse. Apparently there is no threshold value of time until relapse predicting favorable outcome, but rather a continuous increase of CR rates with duration of first remission. In children with relapses after more than 2 years, CR rates still increase up to more than 90%. Thus, we found that patients with late relapse have the same chance of achieving complete remission as those with de novo AML. This finding is of particular importance for reporting experimental therapies since results of treatment in relapsed AML may largely depend on the inclusion of late or early relapse patients in the study.
